CapsoVision, Inc. (CV) AI Stock Analysis

• Market Cap: $214.69M
• Dividend Yield: N/A
• Average Volume (3M): 45.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.07
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 90
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): -0.17
• Shares Outstanding: 46,774,067
• 10 Day Avg. Volume: 21,973
• 30 Day Avg. Volume: 45,470
• PEG Ratio: 0.00
• Price to Book (P/B): -1.04
• Price to Sales (P/S): 11.50
• P/FCF Ratio: -6.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 9.09% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $4.50 ▼(-18.18% Downside)

The overall stock score is primarily impacted by the company's poor financial performance, which poses significant risks. While technical analysis indicates positive momentum, the lack of valuation data and financial challenges weigh heavily on the score.

Positive Factors

Innovative Product Offering

CapsoVision's focus on innovative imaging solutions like CapsoCam positions it well in the medical technology sector, potentially driving long-term growth through advanced diagnostic capabilities.

Diverse Revenue Streams

CapsoVision's diverse revenue streams, including product sales and partnerships, provide a stable foundation for growth and resilience against market fluctuations.

Revenue Growth

Despite financial challenges, a 20.5% revenue growth indicates strong demand for CapsoVision's products, suggesting potential for future market expansion.

Negative Factors

Negative Profitability

Persistent negative profitability and weak financial metrics threaten CapsoVision's long-term viability, necessitating operational improvements to ensure sustainability.

Weak Balance Sheet

A negative stockholders' equity indicates financial instability, posing risks to CapsoVision's ability to fund operations and invest in growth opportunities.

Liquidity Challenges

Negative cash flows highlight liquidity issues, which could constrain CapsoVision's operational flexibility and ability to invest in future growth initiatives.

CapsoVision, Inc. Business Overview & Revenue Model

Company Description

Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics

How the Company Makes Money

CapsoVision generates revenue primarily through the sale of its CapsoCam capsule endoscopy systems and related disposable products, such as the capsules used in procedures. The company also earns revenue from partnerships with healthcare providers and institutions, which may include training, support services, and bulk purchase agreements. Additionally, CapsoVision may explore collaborations with pharmaceutical companies for research and clinical trials, further diversifying its revenue streams. The company's business model is built on establishing a strong presence in hospitals and outpatient clinics, aiming to create long-term relationships that lead to repeat purchases and ongoing service contracts.

CapsoVision, Inc. Financial Statement Overview

Summary

CapsoVision, Inc. is facing significant financial challenges, with negative profitability, weak balance sheet metrics, and poor cash flow performance. The company needs to address its operational inefficiencies and improve its financial structure to ensure long-term viability.

Income Statement

CapsoVision, Inc. shows a concerning financial performance with negative net profit margins and declining EBIT and EBITDA margins. The company experienced a revenue growth of 20.5% from the previous year, but this was overshadowed by significant losses, indicating inefficiencies in cost management and operations.

Balance Sheet

The balance sheet reflects a negative stockholders' equity, which is a critical concern, indicating that liabilities exceed assets. The debt-to-equity ratio is negative due to the negative equity, and the return on equity is also negative, highlighting poor financial health and potential solvency issues.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, suggesting liquidity challenges. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is closely aligned with net income, but both are negative, which is a red flag for financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023
Income Statement
Total Revenue	9.64M	11.76M	9.75M
Gross Profit	5.22M	6.38M	5.49M
EBITDA	-17.53M	-19.40M	-10.96M
Net Income	-17.92M	-19.90M	-11.30M
Balance Sheet
Total Assets	25.66M	16.80M	21.53M
Cash, Cash Equivalents and Short-Term Investments	17.79M	9.32M	14.56M
Total Debt	978.00K	1.24M	1.51M
Total Liabilities	5.22M	146.31M	131.37M
Stockholders Equity	20.44M	-129.51M	-109.84M
Cash Flow
Free Cash Flow	-15.26M	-20.24M	-11.56M
Operating Cash Flow	-15.18M	-20.09M	-10.80M
Investing Cash Flow	-82.00K	-153.00K	-754.00K
Financing Cash Flow	23.59M	15.07M	20.53M

CapsoVision, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
A	75 Outperform	$43.55B	33.61	20.62%	0.68%	6.73%	3.34%
NVST	64 Neutral	$3.32B	241.63	0.50%	―	4.73%	―
ANGO	61 Neutral	$492.34M	―	-17.10%	―	2.73%	87.03%
CV	52 Neutral	$214.69M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NEUE	49 Neutral	―	―	―	―	-13.83%	87.09%

CapsoVision, Inc. Corporate Events

CapsoVision Seeks FDA Breakthrough Status for CapsoCam

On November 10, 2025, CapsoVision announced the submission of an application to the FDA for Breakthrough Device Designation for its CapsoCam UGI capsule endoscopy system, aimed at early-stage pancreatic cancer detection. This non-invasive technology could significantly impact the early diagnosis of pancreatic ductal adenocarcinoma, one of the deadliest cancers, by providing a patient-friendly alternative to current invasive diagnostic methods. If granted, the designation would expedite the development process and potentially improve survival rates by enabling earlier detection and treatment.

The most recent analyst rating on (CV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

CapsoVision Appoints David Garcia as Finance VP

On November 3, 2025, CapsoVision, Inc. announced the appointment of David Garcia as its Senior Vice President of Finance, who will also serve as the principal financial officer and principal accounting officer. Mr. Garcia brings over 20 years of financial leadership experience, having previously worked at Matterport, Inc., View, Inc., Intelepeer Cloud Communications, and Align Technology. His appointment is seen as a strategic move to support CapsoVision’s growth and development pipeline, leveraging his expertise in financial management and capital markets.

The most recent analyst rating on (CV) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

CapsoVision Announces Leadership Transition Plans

On September 22, 2025, CapsoVision, Inc. announced the planned retirement of Rebecca Petersen, its Senior Director of Clinical Affairs, effective October 15, 2025. Keri Jorgenson has been promoted to Director of Clinical Operations and will lead the clinical development operations, ensuring a seamless transition. Petersen will continue to support the company through a consulting agreement starting October 16, 2025, to facilitate a smooth transition without disrupting operations.

The most recent analyst rating on (CV) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

CapsoVision CFO Kevin Lundquist Steps Down

On August 27, 2025, Kevin Lundquist stepped down as Chief Financial Officer of CapsoVision, Inc. The company has initiated a search for his successor and agreed on a separation package with Lundquist, which includes severance benefits, a prorated bonus, stock option vesting, and continued healthcare coverage. Lundquist will also provide consulting support to the company for up to six months as part of a Consulting Agreement.

The most recent analyst rating on (CV) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

CapsoVision Reports Revenue Growth and IPO Success

CapsoVision, Inc. is a commercial-stage medical technology company specializing in advanced imaging and AI-enabled capsule endoscopy solutions, primarily in the gastrointestinal diagnostics sector, with a focus on non-invasive procedures and panoramic imaging technology.